Want to join the conversation?
$MRK announced results from two major studies of Keytruda, its anti-PD-1 therapy, in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) at the ESMO 2016 Congress. $MRK is now advancing multiple registration-enabling studies in NSCLC with Keytruda as monotherapy and in combination.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.